Navigation Links
EntreMed Receives Notice of NASDAQ Compliance
Date:10/15/2010

statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including  the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid® resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Contact:Ginny DunnAssociate DirectorCorporate Communications & Investor Relations240-864-2643
'/>"/>
SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Colo. , July 6, 2015 ... encorafenib, was showcased this past weekend at the ... an oral presentation.  At the meeting, data were ... data from a 100-patient randomized Phase 2 expansion ... and cetuximab, an EGFR inhibitor, with or without ...
(Date:7/6/2015)... July 6, 2015 Akcea Therapeutics, a ... ISIS ), announced today that the U.S. Food ... to volanesorsen (ISIS-APOCIII Rx ) for the treatment ... is a rare genetic disease characterized by extremely ... a Phase 2 study published in the NEJM ...
(Date:7/4/2015)... , España, July 4, 2015 ... a la quimioterapia de primera línea para pacientes ... hígado (mCRC) extiende la supervivencia libre de progresión ... cáncer colorrectal metastásico no resecable (mCRC) que se ... mejora en la supervivencia libre de progresión (PFS) ...
Breaking Medicine Technology:Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 2El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 3El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 5
... SAN DIEGO, Sept. 30 Cadence Pharmaceuticals, Inc. (Nasdaq: ... developing and commercializing proprietary product candidates principally for use ... host a live webcast of its Analyst Day on ... Cadence,s senior management team, led by Ted Schroeder, ...
... Sept. 30 Fifty-nine percent ... by general practitioners, according to a research report published ... study, conducted by researchers from Thomson Reuters and the ... analyzed prescribing patterns for psychotropic drugs from August 2006 ...
Cached Medicine Technology:Cadence Pharmaceuticals to Webcast October 7th Analyst Day 2Cadence Pharmaceuticals to Webcast October 7th Analyst Day 3General Practitioners Write Most Prescriptions for Mental Health Drugs, According to Study from Thomson Reuters and SAMHSA 2
(Date:7/6/2015)... ... July 06, 2015 , ... The School of ... to support a three-year effort to reduce rates of diabetes and cardiovascular disease ... partnership with the Morehouse School of Medicine’s Prevention Research Center and the Satcher ...
(Date:7/6/2015)... ... ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella injectable to his ... to dissolve fat cells and is the first of its kind to be approved ... known as a double chin. Dr. Green participated in clinical trials for Kybella and ...
(Date:7/6/2015)... News, VA (PRWEB) , ... July 06, 2015 ... ... today that Dr. Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® PedFuse® ... Secours Mary Immaculate Hospital in Newport News, VA. The procedure was an L5-S1 ...
(Date:7/6/2015)... ... July 06, 2015 , ... Thanks to donations and a generous grant ... Music & Memory Certification for hospice patients and adult day center participants. , The ... to patients but also to their families and volunteers. Music & Memory is a ...
(Date:7/5/2015)... MN (PRWEB) , ... July 06, 2015 , ... ... the ancillary benefits market, is excited to announce the next generation of PrimeStar ... and Advantage plans to now include two network options—Maximum Allowable Charge (MAC) and ...
Breaking Medicine News(10 mins):Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2
... more than 25 countries will converge on Boston ... 2008 Annual,Conference & Exhibition. The annual event is ... in the healthcare product sector., The regulatory ... job responsibilities related to ensuring that healthcare,products in ...
... become a "difficult patient" before she could get her physicians ... , And once the diagnosis was made, she had to ... she could get the best treatment for scleroderma, a chronic ... major element. , Mayer, a research assistant professor of health ...
... Clinics of Georgia is proud to announce Dr. Chad Levitt, a ... RCOG,s Cumming, GA. Dr. Levitt specializes in head & neck, breast, ... ... Atlanta, GA. (PRWEB) September 10, 2008 -- Board Certified Radiation Oncologist ...
... specializing in risk assessment for diabetics, recently announced that The Hope ... provide retinal imaging risk assessment. , ... Wake Forest, ... Healthcare, a Wake Forest, NC company specializing in risk assessment for ...
... Steve Poizner Will Present Keynote Address at the 6th Annual California ... event is open to the public and brings together over 500 ... lively discussion, and networking. , ... Huntington Beach, CA ...
... BOSTON, Mass. (Sep. 10, 2008)In recent years, private ... investment opportunities. Spurred by investigative reports and anecdotal ... of care, many companies have found themselves under ... a new study, such conclusions may be premature. ...
Cached Medicine News:Health News:Healthcare Product Regulatory Professionals to Convene in Boston for RAPS Annual Conference & Exhibition 2Health News:Healthcare Product Regulatory Professionals to Convene in Boston for RAPS Annual Conference & Exhibition 3Health News:Survival instincts propel 'difficult patient' to insist on quality care 2Health News:Survival instincts propel 'difficult patient' to insist on quality care 3Health News:Dr. Chad Levitt Joins North Georgia Radiation Oncology Center 2Health News:Dr. Chad Levitt Joins North Georgia Radiation Oncology Center 3Health News:The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients 2Health News:Council on Education in Management Announces Insurance Commissioner Steve Poizner Will Present Keynote Address at the 6th Annual California Workers' Comp Forum 2Health News:Private equity companies purchase nursing homes, but care does not suffer 2Health News:Private equity companies purchase nursing homes, but care does not suffer 3
An automatic system for determining erythrocyte sedimentation rate (ESR) in EDTA tube and using cell counter racks....
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
The MICROsed-System is the ideal system back up support to be used as front-line instrument with small workloads....
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: